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Clinical response to calcium channel blockers in  
a hemodynamically unstable patient with reactive 
idiopathic pulmonary arterial hypertension
Grzegorz Kopec, Marcin Waligóra, Anna Tyrka, Monika Komar, Natasza Herman, Piotr Podolec 
Acute vasoreactivity testing is indicated in patients with idiopathic 
pulmonary arterial hypertension (IPAH) to identify subjects who will re-
spond favorably to long-term treatment with calcium channel blockers 
(CCB) [1]. The result of the test determines the choice of treatment and 
predicts survival of the patient [2, 3]. It has been suggested that mo-
lecular etiology of IPAH is different in patients who respond or do not 
respond to CCB treatment [4]. In the current guidelines [1, 5] acute va-
soreactivity testing is recommended in all patients with IPAH but treat-
ment with CCB is advised only in those in World Health Organization 
functional class (WHO-FC) I–III. No guidelines are provided for patients 
with positive acute vasoreactivity testing who are in WHO-FC IV or who 
are hemodynamically unstable.
We present a case of a 29-year-old woman who was urgently admit-
ted to the reference center for pulmonary hypertension from her local 
hospital due to rapidly progressing dyspnea and recurrent episodes of 
syncope. Her symptoms started 2 months before and progressed to 
WHO-FC IV at the time of admission. She presented with resting dyspnea, 
blood pressure of 90/60 mm Hg, a heart rate of 85 beats per minute and 
arterial blood saturation of 95%. The electrocardiogram showed sinus 
rhythm with an incomplete right bundle branch block. Echocardiography 
showed typical signs of precapillary pulmonary hypertension with right 
ventricular dysfunction (Table I). N-terminal pro b-type natriuretic pep-
tide (NT-proBNP) was significantly elevated (Table I). On the first day of 
hospitalization the patient experienced syncope after minimal exertion. 
It was followed by prolonged hypotension which required management 
with intravenous fluid and continuous infusion of dobutamine. After 
hemodynamic stabilization, still on dobutamine, she underwent further 
diagnostic tests according to the current guidelines [1]. She was HIV neg-
ative; pulmonary function tests and lung perfusion scans were normal. 
Abdominal USG and laboratory tests excluded liver disease. Physical ex-
amination and laboratory tests did not suggest a diagnosis of connective 
tissue disease. Echocardiography was negative for congenital heart dis-
ease. These results together with right heart catheterization (day 4) con-
firmed the diagnosis of IPAH (Table I) [6]. Acute pulmonary vasoreactivity 
(20 ppm of nitric oxide over 5 min) was positive. Mean pulmonary artery 
pressure decreased from 49 mm Hg to 26 mm Hg without a change in 
the cardiac index (2.1 l/min/m2). We started treatment with amlodipine 
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 Systolic          Diastolic
 Dose of dobutamine [µg/kg/min]          Dose of amlodipine [mg]
Figure 1. Monitoring of systemic arterial pressure. The pressure was stabilized on dobutamine infusion and then 
maintained despite starting treatment with amlodipine
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Table I. Functional and hemodynamic status of the patient at admission and at 3-month follow-up
Parameter Baseline 3-month follow-up
Functional status:
WHO-FC IV II
6MWD [m] 0 at admission; 
370 m at discharge 
450
Echocardiography:
Proximal RVOT [mm] 34 29
TAPSE [mm] 14 17
RAA [cm2] 24 17
PAd [mm] 42 28 
RVSP [mm Hg] 88 55
Pericardial fluid Present Absent
NT-proBNP [pg/ml] 3141* 132*
Right heart catheterization:
PAP s/m/d [mm Hg] 72/49/38 53/29/18
Mean RAP [mm Hg] 1 1
CI [l/min/m2] 2.1 2.9
Mean PAWP [mm Hg] 10 8
PVR [WU] 10.2 3.9 
SVR [WU] 25.9 16.7
SpO2 in pulmonary artery [%] 66 72
Systemic pressure s/m/d [mm Hg] 120/97/85 111/89/78
CI – cardiac index, PAd – pulmonary artery diameter, PAP – pulmonary artery pressure, PAWP – pulmonary artery wedge pressure, PVR – 
pulmonary vascular resistance, RAA – right atrium area, RAP – right atrial pressure, RVOT – right ventricular outflow tract, RVSP – right 
ventricular systolic pressure, SpO
2
 – oxygen saturation, s/m/d – systolic/mean/diastolic, SVR – systemic vascular resistance, TAPSE – 
tricuspid annular plane systolic excursion; *the upper reference limit is 125 pg/ml.
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2.5 mg while continuing inotropic support. After 
2 days we were able to stop dobutamine infusion 
(Figure 1). At discharge the dose of amlodipine 
was 20 mg, and the patient was in WHO-FC II with 
6 min walk distance of 370 m. The dose of am-
lodipine was increased in the outpatient clinic up 
to 40 mg daily. Three months follow-up showed 
marked hemodynamic and functional improve-
ment, as shown in Table I. At 12 months follow-up 
the patient was at WHO-FC I, with 6 min walking 
distance of 490 m and no episodes of syncope.
Observational studies showed a  long-term 
benefit from CCB therapy in stable patients with 
vasoreactive IPAH at WHO-FC I–IV [3]. Our report is 
the first to present successful treatment with CCB 
of a hemodynamically compromised patient with 
vasoreactive IPAH. Based on this observation we 
suggest that in patients with vasoreactive IPAH 
an attempt of CCB therapy should be considered 
even when hemodynamic stabilization is depen-
dent on inotropic support. The treatment should 
be closely monitored and prostacyclin therapy 
should be started in case of treatment failure with 
CCB [1, 7]. 
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